December 4, 2014
Shedding light on AID off-targeting and lymphoma
By: Paul Guttry
Researchers in the laboratory of Frederick Alt at the Howard Hughes Medical Institute and Program in Cellular and Molecular Medicine (PCMM) at Boston Children's Hospital, led by Feilong Meng and in collaboration with teams at several other major centers working on the genetics of immunology and cancer, have identified a relationship between sites of convergent gene transcription, the presence of intragenic super-enhancers, and the mis-targeting of the mutagenic activity of activation-induced cytidine deaminase (AID).
December 18, 2014
On the hunt for gene editing's collateral damage
By: Tom Ulrich
Labs the world over are jumping on the gene editing bandwagon (and into the inevitable patent arguments). And it's hard to blame them. As these technologies have evolved over the last two decades starting with the zinc finger nucleases (ZFNs), followed by transcription activator-like effector nucleases (TALENs) and CRISPR—they've become ever more powerful and easier to use.
But one question keeps coming up: How precise are these systems? After all, a method that selectively mutates, deletes or swaps specific gene sequences (and now can even turn genes on) is only as good as its accuracy.